Deep immune profiling of chronic rhinosinusitis in allergic and non-allergic cohorts using mass cytometry.

Allergy Chronic rhinosinusitis Cytokines Mass cytometry Peripheral blood mononuclear cells Polyps

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
08 Mar 2024
Historique:
received: 19 01 2024
revised: 19 02 2024
accepted: 20 02 2024
pubmed: 11 3 2024
medline: 11 3 2024
entrez: 10 3 2024
Statut: aheadofprint

Résumé

Chronic rhinosinusitis (CRS) is a persistent nasal and paranasal sinus mucosa inflammation comprising two phenotypes, namely CRS with nasal polyps (CRSwNP) and without (CRSsNP). CRSwNP can be associated with asthma and hypersensitivity to non-steroidal anti-inflammatory drug (NSAID) in a syndrome known as NSAID-exacerbated respiratory disease (N-ERD). Furthermore, CRS frequently intertwines with respiratory allergies. This study investigated levels of 33 different nasal and serum cytokines and phenotypic characteristics of peripheral blood mononuclear cells (PBMCs) within cohorts of CRS patients (n = 24), additionally examining the influence of comorbid respiratory allergies by mass cytometry. N-ERD patients showed heightened type 2 nasal cytokine levels. Mass cytometry revealed increased activated naive B cell levels in CRSwNP and N-ERD, while resting naive B cells were higher in CRSsNP. Th2a cell levels were significantly elevated in allergic subjects, but not in CRS groups. In conclusion, there are distinct immunological features in PBMCs of CRS phenotypes and allergy.

Identifiants

pubmed: 38462155
pii: S1521-6616(24)00065-2
doi: 10.1016/j.clim.2024.110174
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110174

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest SS served as a speaker and/or consultant and/or advisory board member for Sanofi, GSK, and Novartis. SS is an investigator for Novartis and AstraZeneca (grants paid to his institution). JED served as a speaker and/or consultant and/or advisory board member for Sanofi, Allergopharma, AstraZeneca, GSK, and Novartis. JED is an investigator for Novartis and AstraZeneca (grants paid to her institution).

Auteurs

Fana Alem Kidane (FA)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Lena Müller (L)

Core Facilities, Medical University of Vienna, Vienna, Austria.

Marianne Rocha-Hasler (M)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Aldine Tu (A)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Victoria Stanek (V)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Nicholas Campion (N)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Tina Bartosik (T)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Mohammed Zghaebi (M)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Slagjana Stoshikj (S)

Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Daniela Gompelmann (D)

Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Andreas Spittler (A)

Core Facilities, Medical University of Vienna, Vienna, Austria; Department of Surgery, Research Lab, Medical University of Vienna, Vienna, Austria.

Marco Idzko (M)

Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Julia Eckl-Dorna (J)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria. Electronic address: julia.eckl-dorna@meduniwien.ac.at.

Sven Schneider (S)

Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.

Classifications MeSH